Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms
暂无分享,去创建一个
Yeul-Hong Kim | J. Seo | U. Jo | K. Park | Jong-Kuk Park | J. Park | Jinho Kang | H. Lee | I. Kim | Jong Kuk Park
[1] F. Sotgia,et al. Oncogenes induce the cancer-associated fibroblast phenotype: Metabolic symbiosis and “fibroblast addiction” are new therapeutic targets for drug discovery , 2013, Cell cycle.
[2] F. Beca,et al. Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: Key events in the progression from an in situ to an invasive breast carcinoma , 2013, Cell cycle.
[3] Xuelei Ma,et al. Prognostic role of caveolin in breast cancer: a meta-analysis. , 2013, Breast.
[4] L. Lum,et al. A Targeted RNAi Screen of the Breast Cancer Genome Identifies KIF14 and TLN1 as Genes That Modulate Docetaxel Chemosensitivity in Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.
[5] J W Gray,et al. CpG island shore methylation regulates caveolin-1 expression in breast cancer , 2012, Oncogene.
[6] V. Speirs,et al. Clinical and functional significance of loss of caveolin‐1 expression in breast cancer‐associated fibroblasts , 2012, The Journal of pathology.
[7] S. Dakshanamurthy,et al. Tyrosine-phosphorylated Caveolin-1 (Tyr-14) Increases Sensitivity to Paclitaxel by Inhibiting BCL2 and BCLxL Proteins via c-Jun N-terminal Kinase (JNK)* , 2012, The Journal of Biological Chemistry.
[8] R. Moorehead,et al. Caveolin-1 expression is elevated in claudin-low mammary tumor cells , 2012, Cancer Cell International.
[9] F. Sotgia,et al. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. , 2012, Annual review of pathology.
[10] Yuan Qi,et al. Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer , 2010, Clinical Cancer Research.
[11] E. Álava,et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer , 2010, Breast Cancer Research and Treatment.
[12] G. Hortobagyi,et al. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] B. Goh,et al. Correlation of RRM1 promoter region single nucleotide polymorphisms (SNPs) with response and outcome in breast cancer patients treated with gemcitabine-based chemotherapy , 2008 .
[14] Y. Fujii,et al. The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. , 2007, Oncology reports.
[15] Robert Clarke,et al. Caveolin-1 Tyrosine Phosphorylation Enhances Paclitaxel-mediated Cytotoxicity* , 2007, Journal of Biological Chemistry.
[16] Robin L. Jones,et al. Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis , 2007, Clinical Cancer Research.
[17] S. Merajver,et al. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer , 2006, Breast Cancer Research and Treatment.
[18] S. Kim,et al. Caveolin‐1 is down‐regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast , 2005, Histopathology.
[19] John N. Hutchinson,et al. Caveolin-1 Gene Disruption Promotes Mammary Tumorigenesis and Dramatically Enhances Lung Metastasis in Vivo , 2004, Journal of Biological Chemistry.
[20] J. Gligorov,et al. Preclinical pharmacology of the taxanes: implications of the differences. , 2004, The oncologist.
[21] G. Fiucci,et al. Up-regulation of Caveolae and Caveolar Constituents in Multidrug-resistant Cancer Cells* , 1998, The Journal of Biological Chemistry.
[22] M. Lisanti,et al. Upregulation of caveolin‐1 and caveolae organelles in Taxol‐resistant A549 cells , 1998, FEBS letters.
[23] C. Croce,et al. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. , 1996, Cancer research.
[24] D. Baltimore,et al. Reduction of caveolin and caveolae in oncogenically transformed cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[25] Chih-Hsin Yang,et al. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. , 2008, Lung cancer.
[26] K. Lyseng-Williamson,et al. Docetaxel: a review of its use in metastatic breast cancer. , 2005, Drugs.